Insulin inhalation - Abbott Laboratories

Drug Profile

Insulin inhalation - Abbott Laboratories

Alternative Names: KI 02 212

Latest Information Update: 11 Sep 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kos Pharmaceuticals
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 24 Jul 2013 Biomarkers information updated
  • 13 Dec 2006 Kos Pharmaceuticals has been acquired by Abbott Laboratories
  • 31 Mar 2005 Kos Pharmaceuticals has filed an IND with the US FDA for diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top